Linden Thomas Advisory Services’s Insulet PODD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.48M Buy
16,314
+7,024
+76% +$1.17M 0.2% 155
2026
Q1
$1.95M Buy
9,290
+479
+5% +$120K 0.19% 197
2025
Q4
$2.5M Sell
8,811
-114
-1% -$35.6K 0.25% 110
2025
Q3
$2.76M Buy
8,925
+26
+0.3% +$8.15K 0.28% 103
2025
Q2
$2.8M Sell
8,899
-155
-2% -$44.7K 0.31% 88
2025
Q1
$2.38M Buy
9,054
+330
+4% +$89.3K 0.31% 95
2024
Q4
$2.28M Sell
8,724
-83
-0.9% -$20.9K 0.29% 103
2024
Q3
$2.05M Sell
8,807
-5
-0.1% -$1.03K 0.28% 117
2024
Q2
$1.78M Buy
8,812
+3,497
+66% +$630K 0.27% 125
2024
Q1
$911K Sell
5,315
-502
-9% -$93.6K 0.15% 279
2023
Q4
$1.26M Buy
5,817
+73
+1% +$12.5K 0.24% 184
2023
Q3
$916K Sell
5,744
-225
-4% -$50.4K 0.2% 208
2023
Q2
$1.72M Buy
5,969
+76
+1% +$23.1K 0.38% 65
2023
Q1
$1.88M Buy
5,893
+505
+9% +$150K 0.47% 53
2022
Q4
$1.59M Buy
+5,388
New +$1.49M 0.45% 63

Other funds holding PODD

Linden Thomas Advisory Services's PODD Position: Q2 2026 in Review

Linden Thomas Advisory Services increased its Insulet (PODD) stake by 76% in Q2 2026, buying an estimated $1.17M and bringing the position to 16,314 shares worth $2.48M. The position accounts for 0.2% of the portfolio, ranked #155.

Linden Thomas Advisory Services first reported a position in PODD in Q4 2022 and has held it in 15 quarters since. The position peaked at $2.8M in Q2 2025. 139 funds tracked by Wall St. Rank hold PODD as of Q2 2026.

  • Linden Thomas Advisory Services held 16,314 shares of Insulet worth $2.48M as of Q2 2026.
  • Linden Thomas Advisory Services bought 7,024 Insulet shares in Q2 2026, an estimated $1.17M.
  • Insulet made up 0.2% of Linden Thomas Advisory Services's portfolio in Q2 2026, its #155 holding.
  • Linden Thomas Advisory Services first reported a position in Insulet in Q4 2022 and has held it in 15 quarters since.
  • Linden Thomas Advisory Services's Insulet position peaked at $2.8M in Q2 2025.
  • 139 funds tracked by Wall St. Rank held Insulet as of Q2 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.